Literature DB >> 17085259

Acute lung injury and the acute respiratory distress syndrome: challenges in clinical trial design.

Todd W Rice1, Gordon R Bernard.   

Abstract

Despite significant advances in the understanding of the complex pathophysiology, only a limited number of new treatments for acute lung injury (ALI) have emerged in the last 2 decades. This article discusses some of the challenges that remain in conducting clinical research in patients who have ALI and acute respiratory distress syndrome. New definitions that incorporate prognostic measures and reduce patient heterogeneity will allow more efficient enrollment of patients. Delineating outcomes attributable to the lung injury will improve the power of studies to detect significant treatment effects. Future collaborative studies will be needed to investigate longer-term clinical outcomes.

Entities:  

Mesh:

Year:  2006        PMID: 17085259     DOI: 10.1016/j.ccm.2006.06.006

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  4 in total

1.  An alternative method of acute lung injury classification for use in observational studies.

Authors:  Chirag V Shah; Paul N Lanken; A Russell Localio; Robert Gallop; Scarlett Bellamy; Shwu-Fan Ma; Carlos Flores; Jeremy M Kahn; Barbara Finkel; Barry D Fuchs; Joe G N Garcia; Jason D Christie
Journal:  Chest       Date:  2010-06-24       Impact factor: 9.410

2.  Urinary trypsin inhibitor attenuates lipopolysaccharide-induced acute lung injury by blocking the activation of p38 mitogen-activated protein kinase.

Authors:  Xinying Zhang; Fengqin Liu; Haiyan Liu; Hongxia Cheng; Wei Wang; Qiang Wen; Yulin Wang
Journal:  Inflamm Res       Date:  2011-01-19       Impact factor: 4.575

3.  Plasma C-reactive protein levels are associated with improved outcome in ARDS.

Authors:  Ednan K Bajwa; Uzma A Khan; James L Januzzi; Michelle N Gong; B Taylor Thompson; David C Christiani
Journal:  Chest       Date:  2009-05-01       Impact factor: 9.410

4.  Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trials.

Authors:  Daren K Heyland; John Muscedere; John Drover; Xuran Jiang; Andrew G Day
Journal:  Crit Care       Date:  2011-03-18       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.